Research paperStigma at every turn: Health services experiences among people who inject drugs
Introduction
Stigmatization of people who use drugs is increasingly recognized as a serious public health issue. In the United States, substance use problems carry more stigma than other mental health problems (Barry, McGinty, Pescosolido, & Goldman, 2014; Link, Phelan, Bresnahan, Stueve, & Pescosolido, 1999), and manifest in pervasive stereotypes, prejudice, and discrimination. Many Americans indicate that they desire social distance from individuals who use drugs (Barry et al., 2014; Corrigan, Kuwabara, & O’Shaughnessy, 2009; Link et al., 1999), and are afraid of those with drug use problems, viewing them as dangerous (Corrigan et al., 2009; Link et al., 1999). People who use drugs are seen as unworthy of receiving assistance (e.g., finding jobs or housing), and public policies designed to help them are widely opposed (Barry et al., 2014; Corrigan et al., 2009). Stigma against drug users is reinforced structurally by laws that criminalize people struggling with drug addiction and permit discrimination against them (Leis & Rosenbloom, 2009). People who use drugs report that such discrimination affects them more than discrimination related to race, sex, sexual orientation, poverty, incarceration history, or mental illness (Minior, Galea, Stuber, Ahern, & Ompad, 2003; Young, Stuber, Ahern, & Galea, 2005).
Many conceptualizations of stigma have been proposed since Erving Goffman established it as a sociological construct, defining stigma as “an attribute that is deeply discrediting” (1963, p. 3). Subsequent scientific literature on substance use and mental illness suggests that multiple types of stigma operate at both the structural and individual levels (Kulesza, Larimer, & Rao, 2013). At the structural level, public stigma describes cultural norms that negatively affect stigmatized groups, including widely-held stereotypes and prejudices (Corrigan & Watson, 2002). Perceived stigma (or felt stigma) is a belief on the part of a person with a stigmatized identity that the general population ascribes to negative stereotypes about people with that identity (Livingston & Boyd, 2010). For example, a person who uses drugs may endorse the statement that “most people believe that drug addicts cannot be trusted” (Link, Struening, Rahav, Phelan, & Nuttbrock, 1997). Enacted stigma, which operates at both structural and individual levels, is the experience of discrimination or rejection related to a stigmatized identity (Luoma et al., 2007). Finally, individual-level self-stigma (or internalized stigma) results when members of a stigmatized group accept stigmatizing attributions about themselves and believe them to be true (Corrigan & Watson, 2002).
Literature on stigma and drug use suggests that drug users experience multiple types of stigma, and these experiences are associated with adverse health outcomes. Studies of people who use drugs and alcohol have found that enacted stigma, perceived stigma, and self-stigma are associated with mental health problems, including increased depressive symptoms (Ahern, Stuber, & Galea, 2007; Latkin, Davey-Rothwell, Yang, & Crawford, 2013; Link et al., 1997; Luoma et al., 2007; Young et al., 2005). Enacted stigma is also associated with poor physical health among drug users (Ahern et al., 2007; Young et al., 2005).
Stigma may play a role in maintaining substance use disorders and increasing the likelihood of relapse. Studies have identified stigma as a barrier to engaging in substance use treatment (Browne et al., 2016; Keyes et al., 2010; Radcliffe & Stevens, 2008; Semple, Grant, & Patterson, 2005) and associated it with continued drug use after treatment (Kulesza, Ramsey, Brown, & Larimer, 2014). People who use drugs may also experience stigma from participating in drug treatment, particularly opioid substitution therapy. For example, although methadone maintenance is an evidence-based treatment for opioid use disorders (Amato et al., 2005; Connery, 2015; Veilleux, Colvin, Anderson, York, & Heinz, 2010), it is widely viewed as an alternative form of addiction. As a result, methadone patients experience many of the same forms of stigma as people who use illicit drugs (Conner & Rosen, 2008; Earnshaw, Smith, & Copenhaver, 2013; Etesam, Assarian, Hosseini, & Ghoreishi, 2014; Vigilant, 2004). This stigma around methadone has long been a barrier to its implementation and use (Joseph, Stancliff, & Langrod, 2000).
People who inject drugs (PWID) experience greater levels of stigma than those who use drugs through non-injection routes like smoking or snorting (Etesam et al., 2014; Luoma et al., 2007), and this stigma has unique implications for health. PWID are at high risk of HIV, hepatitis C virus (HCV), and bacterial infections from sharing and/or reusing syringes, and stigma may play a role in increasing risk. For example, one study found that self-stigma among PWID was associated with lower utilization of pharmacies and syringe exchange programs (SEPs) to obtain sterile syringes (Rivera, De Cuir, Crawford, Amesty, & Lewis, 2014). Additionally, drug use stigma is associated with risky injection behaviors, including sharing syringes and other injection supplies, among PWID (Latkin et al., 2010).
Given the growing body of literature associating stigma with negative health outcomes, it is important to understand how PWID experience stigma and the processes by which stigma affects their health. Healthcare settings are an especially important context in which to study stigma’s impact, as there are a variety of health complications associated with injection that require medical intervention. Previous research indicates that health professionals often have negative attitudes toward people with substance use disorders (for a review, see van Boekel, Brouwers, van Weeghel, & Garretsen, 2013). These attitudes are associated with serious consequences for PWID, such as lower rates of exposure to life-saving medications like highly active antiretroviral therapy (Ding et al., 2005).
Nonetheless, there is still very little research assessing the impact of stigma on PWID health behaviors. Lloyd (2013) identified a small number of studies from Europe and Canada that examined PWID experiences of stigma in pharmacies and other healthcare settings. Most related literature from the U.S. has examined the attitudes of healthcare workers rather than the experiences of drug users themselves (see Lloyd, 2013 and van Boekel et al., 2013). We are aware of at least one U.S. study that examined drug user experiences in healthcare settings (Weiss, McCoy, Kluger, & Finkelstein, 2004), but none have specifically addressed the experiences of PWID across such settings. Additionally, we identified only two international studies examining PWID experiences of stigma in retail pharmacies (excluding pharmacy-based SEPs; Davidson et al., 2012; Matheson, 1998), and none that have done so in the U.S. It is notable, then, that stigma emerged as a key factor influencing access to and utilization of a variety of health-related services (including nonprescription syringe sales) in our interviews with PWID in the Central Valley of California. Herein, we explore how stigma is experienced by PWID within the health services system and its impact on health behaviors.
Section snippets
Study setting
Injection drug use is a prominent health concern in California’s Central Valley. In a study of 96 U.S. metropolitan statistical areas (MSAs), the Fresno and Bakersfield MSAs both ranked in the top four in prevalence of injection drug use (2.95% and 2.40%, respectively) (Brady et al., 2008). Fresno (population ∼510,000) in Fresno County and Bakersfield (population ∼364,000) in Kern County are the main urban hubs in this predominantly rural and agricultural region.
Many Central Valley communities
Methods
The overarching purpose of our study was to examine SB41 implementation from the perspectives of both pharmacy staff and PWID. To this end, we used a multi-phase, sequential mixed methods research design (Creswell & Clark, 2010; Ivankova, Creswell, & Stick, 2006) to characterize impacts on implementation at multiple levels. Our inquiry was guided by a “risk environment” framework, which views drug use and associated harms as a product of social and environmental interactions at macro, meso and
Results
Among 46 PWID, the average age was 38.7 years (range: 20–65) and 37% were female (n = 17). Sixty-three percent identified as white (n = 29) and 37% as Latino (n = 17). Past month injection drug use included heroin (67%, n = 31), methamphetamine (50%, n = 23), and powder cocaine (20%, n = 9). Participants had injected an average of 16.7 years (range: 1 month – 54 years). We applied the stigma code in 28 out of 46 interview transcripts. Participants who cited stigma were similar to other
Syringe access
Participants repeatedly cited stigma when discussing syringe access, especially in the context of meso-level pharmacist interactions. Participants perceived that pharmacists made judgments based on appearance and refused to sell syringes to individuals they suspected were PWID. Some reported changing their appearance before attempting syringe purchase, including covering tattoos and injection stigmata (e.g., injection-related scars) and dressing conservatively. One participant said it was
Medical care
Medical care was another area in which stigma was discussed repeatedly. Multiple participants indicated that first responders and hospital staff treat PWID poorly and with disdain. These experiences ranged from receiving “looks” from staff that participants perceived as stigmatizing to receiving medical care they believed was substandard due to their categorization as a drug user. Participants also gave glimpses into how these experiences influenced their micro-level health-related behaviors.
Methadone treatment
Participants reported that stigma created barriers to engaging in drug treatment and recovery support. They described meso-level group norms among PWID in which participating in methadone treatment was more stigmatized than injecting drugs. They also described meso-level stigma within the context of other drug treatment and support programs that were hostile to or exclusive of individuals on methadone.
Multiple participants described the core beliefs that underlie macro-level public stigma
Discussion
Stigma played an undeniably important role in our participants’ experiences with health services, arising organically across interviews even though we did not ask about it directly. Our findings indicate that stigma has an impact on multiple aspects of life and health among PWID, including utilization of health-related services such as syringe access, medical care, and drug treatment. In each of these areas, stigma was linked directly by participants to micro-level health risk behaviors, lower
Conclusions
PWID in our study reported pervasive perceptions and experiences of stigma in the context of health services in California’s Central Valley. This stigma was linked by participants to decreased health services access and utilization in the areas of sterile syringe access, medical care, and drug treatment. Our study illustrates the need to develop and test interventions that target drug use stigma at all levels of influence.
Declarations of interest
None.
Acknowledgments
This work was supported by the National Institute on Drug Abuse (R01DA035098). The authors wish to thank Patricia Case, Dallas Blanchard, Shantell Waldo, Dennis Hendrix, Bill Wood, Kevin Freeman, and all of the participants who made this study possible.
References (53)
- et al.
Stigma, discrimination and the health of illicit drug users
Drug and Alcohol Dependence
(2007) - et al.
An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research
Journal of Substance Abuse Treatment
(2005) Nonprescription syringe sales: Resistant pharmacists' attitudes and practices
Drug and Alcohol Dependence
(2016)- et al.
Negotiating access: Social barriers to purchasing syringes at pharmacies in Tijuana, Mexico
International Journal of Drug Policy
(2012) - et al.
The relationship between drug use stigma and HIV injection risk behaviors among injection drug users in Chennai, India
Drug and Alcohol Dependence
(2010) - et al.
Correlates and consequences of internalized stigma for people living with mental illness: A systematic review and meta-analysis
Social Science and Medicine
(2010) - et al.
An investigation of stigma in individuals receiving treatment for substance abuse
Addictive Behaviors
(2007) Self-reported participation in voluntary nonprescription syringe sales in California’s Central Valley
Journal of the American Pharmaceutical Association
(2017)- et al.
Are drug treatment services only for ‘thieving junkie scumbags’? Drug users and the management of stigmatised identities
Social Science and Medicine
(2008) The ‘risk environment': A framework for understanding and reducing drug-related harm
International Journal of Drug Policy
(2002)
Internalized stigma and sterile syringe use among people who inject drugs in New York City, 2010–2012
Drug and Alcohol Dependence
Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review
Drug and Alcohol Dependence
A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction
Clinical Psychology Review
The most conservative and liberal cities in the United States
Stigma, discrimination, treatment effectiveness, and policy: Public views about drug addiction and mental illness
Psychiatric Services
Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002
Journal of Urban Health
Barriers and facilitators to substance use treatment in the rural south: A qualitative study
The Journal of Rural Health
Medical, legal, and moral gatekeeping: Pharmacists' construction of the deserving patient
Conference papers − American Sociological Association
You're nothing but a junkie: Multiple experiences of stigma in an aging methadone maintenance population
Journal of Social Work Practice in the Addictions
Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions
Harvard Review of Psychiatry
The paradox of self-stigma and mental illness
Clinical Psychology: Science and Practice
The public stigma of mental illness and drug addiction: Findings from a stratified random sample
Journal of Social Work
Choosing a mixed methods design
Designing and conducting mixed methods research
Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users
Archives of Internal Medicine
Drug addiction stigma in the context of methadone maintenance therapy: An investigation into understudied sources of stigma
International Journal of Mental Health & Addiction
Stigma and its determinants among male drug dependents receiving methadone maintenance treatment
Archives of Iranian Medicine
Cited by (289)
Vaccination coverage among people who inject drugs: A systematic review
2024, International Journal of Drug PolicyDirect-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
2024, The Lancet Gastroenterology and HepatologyMedia framing xylazine as a “zombie drug” is amplifying stigma onto people who use drugs
2024, International Journal of Drug Policy